NCT/Study#

SET101

A Phase 1/1b, Open-Label Multi-Center Two Part Study Of Setd2 Inhibitor Ezm0414 In Subjects With Relapsed/Refractory Multiple Myeloma And Relapsed/Refractory Diffuse Large B Cell Lymphoma

A Phase 1/1b, Open-Label Multi-Center Two Part Study Of Setd2 Inhibitor Ezm0414 In Subjects With Relapsed/Refractory Multiple Myeloma And Relapsed/Refractory Diffuse Large B Cell Lymphoma

DISEASE GROUP:
Phase 1
current phase:
I
STUDY STATUS:
Active
Location:
For More information: